Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab + trastuzumab + ado-trastuzumab emtansine + cetuximab
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This entry refers to the therapeutic regimens evaluated in the Phase Ib/II 'PembroMab' clinical trial (NCT02318901) conducted at the Western Regional Medical Center. The study investigates the combination of the PD-1 inhibitor pembrolizumab with established monoclonal antibodies targeting HER2 (trastuzumab and ado-trastuzumab emtansine) or EGFR (cetuximab). The goal is to leverage the synergistic effects of targeted therapy and immunotherapy in patients with advanced solid tumors, including HER2-positive breast, gastric, and esophageal cancers, as well as head and neck squamous cell carcinoma (HNSCC) and KRAS/NRAS/BRAF wild-type colorectal cancer. By combining checkpoint inhibition with targeted monoclonal antibodies, the regimen aims to enhance the immune system's ability to recognize and destroy cancer cells while simultaneously inhibiting key growth signaling pathways.
- Brand names
- KeytrudaHerceptinKadcylaErbitux
- Other names
- Pembrolizumab combination with monoclonal antibody therapyPembroMab trial regimen
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)EGFR T790M (Epidermal growth factor receptor T790M mutant)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on pembrolizumab + trastuzumab + ado-trastuzumab emtansine + cetuximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab + trastuzumab + ado-trastuzumab emtansine + cetuximab.